Home › NDC Lookup › J-codes › J9044
J9044

J9044 – Injection, bortezomib, not otherwise specified, 0.1 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 11 NDCs crosswalked

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J9044 summary

J9044 is a HCPCS Level II J-code used to bill bortezomib, not otherwise specified, 0.1 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Code J9044 NDC-Crosswalk 11 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ9044
DescriptorInjection, bortezomib, not otherwise specified, 0.1 mg
Billing unitNot available in current dataset
Payment limit / unit Not available in current dataset
Mapped NDCs11
Data periodNot available in current dataset
Last updatedSource date not available

💊 About Bortezomib DRUG GUIDE

Bortezomib is used to treat two types of cancer in adults: multiple myeloma (a cancer of plasma cells in the bone marrow) and mantle cell lymphoma (a type of non-Hodgkin lymphoma).

These indications are shared across the available products — Velcade, Boruzu, and generic bortezomib formulations.Velcade, Boruzu, and bortezomib injections are all approved for both conditions.

Your care team will determine which product and treatment plan is right for your situation.

Read the full Bortezomib drug guide →
Clinical overview from our editorial drug guide for Bortezomib. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS

Medicare payment limit / unit
—
Est. ASP / unit
—
Est. after 2% sequester
—
HCPCS dosage
—
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).
Full HCPCS code details (official CMS record)
Long descriptionInjection, bortezomib, not otherwise specified, 0.1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment group—
Action codeN — No maintenance this year
Effective date2023-01-01
Date added2019-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J9044 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J9044 CROSSWALKED NDCs

11 NDCs map to J9044. Bill units = how many HCPCS units one package represents.
NDC (11-digit)DrugLabelerPackageStrength Bill units NADAC / unit StatusSource
68001-0541-36 Bortezomib 3.5 mg/3.5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION BluePoint 1 VIAL, SINGLE-USE in 1 CARTON (68001-541-... 3.5 mg/3.5mL 35 — ● Active PDAC
00143-9098-01 bortezomib 3.5 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Hikma 1 VIAL in 1 CARTON (0143-9098-01) / 1 INJ... 3.5 mg/1 35 — ● Active PDAC
68001-0540-36 Bortezomib 3.5 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION BluePoint 1 VIAL in 1 CARTON (68001-540-36) / 1 INJ... 3.5 mg/1 35 — ● Active PDAC
50742-0484-01 BORTEZOMIB (SDV,PF,LYOPHILIZED) 3.5 MG Unknown — — 35 — — PDAC
25021-0244-10 BORTEZOMIB (SDV,PF,LATEX-FREE) 3.5 MG Unknown — — 35 — — PDAC
60505-6050-04 BORTEZOMIB 3.5 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Apotex 1 VIAL in 1 CARTON (60505-6050-4) / 1 INJ... 3.5 mg/1 35 — ● Active PDAC
70710-1411-01 BORTEZOMIB 1 mg/mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Zydus 1 VIAL, SINGLE-DOSE in 1 CARTON (70710-141... 1 mg/mL 35 — ● Active PDAC
10019-0991-01 BORTEZOMIB (SDV,PF,LYOPHILIZED) 3.5 MG Unknown — — 35 — — PDAC
55150-0337-01 BORTEZOMIB 3.5 mg/1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION Eugia 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-337... 3.5 mg/1 35 — ● Active PDAC
43598-0865-60 BORTEZOMIB (SDV,LYOPHILIZED) 3.5 MG Unknown — — 35 — — PDAC
63323-0721-10 BORTEZOMIB, (SDV,LATEX-FREE) 3.5 MG Unknown — — 35 — — PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

🗺️ Where J9044 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J9044

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
bortezomib 3
BORTEZOMIB 3
Bortezomib 2
NDC products by labeler
Eugia US LLC 2
Apotex Corp 2
BluePoint Laboratories 2
Hikma Pharmaceuticals USA Inc. 1
Zydus Pharmaceuticals USA Inc. 1

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Not available
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
11 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
No reportable utilization
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J9044 billing FAQ

What is HCPCS code J9044?
J9044 is a HCPCS Level II J-code used to bill Injection, bortezomib, not otherwise specified, 0.1 mg under Medicare Part B and most medical (not pharmacy) benefits.
Which NDCs bill under J9044?
11 NDCs currently map to J9044 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9044 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.